

Special Issue

Liver Transplantation for Cancer: The Future of Transplant Oncology

Message from the Guest Editor

Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a treatment that includes the underlying cirrhosis; theoretically, there is no better treatment. Many studies showed that selected patients with HCC can have improved outcomes after LT. Recently, other hepatobiliary malignancies, such as unresectable perihilar cholangiocarcinoma or liver metastasis for colorectal cancer, have been treated by LT with significant improved outcomes. The concept of such cancer treatment is defined as “transplant oncology”. On the other hand, there are some cautious views that LT for non-HCC malignancies including neuroendocrine tumors should be performed only in high-volume centers under strict selection criteria due to the current shortage of available organs. With this Special Issue, we aim to discuss the selection criteria, pre-LT treatment, appropriate immunosuppressive regimen, and strategies for the follow-up of LT for hepatobiliary malignancies to establish the concept of transplant oncology.

Guest Editor

Prof. Dr. Tomoharu Yoshizumi

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka City 812-8582, Fukuoka, Japan

Deadline for manuscript submissions

closed (30 April 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/153384

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)